Mar 10, 2020 | Press Releases
ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells with N-803, an IL-15 Superagonist First demonstration of durable control of viremia without antiviral therapy in 9 of 13 SHIV-infected monkeys...
Jan 16, 2020 | Press Releases
Complete Responses Noted in Multiple Tumor Types (including Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer, Merkel Cell Cancer, Bladder Cancer, and Non-Hodgkin’s Lymphoma) when Natural Killer cells and T cells are activated simultaneously FDA...
Jan 14, 2020 | Press Releases
World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete response in second-line metastatic pancreatic cancer,...
Dec 16, 2019 | Press Releases
World’s first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation Ongoing durable complete responses ranging from 8 to 11 months observed in TNBC patients who failed standard of care...
Dec 4, 2019 | Press Releases
Results of Phase 1 and 2 studies in BCG Unresponsive Non-Muscle Invasive Bladder Cancer in High Risk Carcinoma in Situ Disease Earn FDA Breakthrough Status for ImmunityBio’s IL-15 Superagonist Complex CULVER CITY, Calif., Dec. 4, 2019 – ImmunityBio, a privately...
Nov 7, 2019 | Press Releases
Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety Culver City, Calif., Nov. 7, 2019 – NantKwest Inc. (Nasdaq: NK), a next generation, clinical-stage...
